NewHydrogen, Inc. - Quarter Report: 2008 June (Form 10-Q)
SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON, D.C.
20549
FORM 10-Q
(Mark
One)
x QUARTERLY REPORT UNDER
SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE
QUARTERLY PERIOD ENDED JUNE 30, 2008
¨ TRANSITION REPORT UNDER
SECTION13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE
TRANSITION PERIOD FROM __________ TO __________
COMMISSION
FILE NUMBER: 333-138910
BIOSOLAR,
INC.
(Name of
registrant in its charter)
Nevada
|
|
20-4754291
|
(State
or other jurisdiction of
incorporation
or organization)
|
|
(I.R.S.
Employer Identification No.)
|
27936 Lost Canyon Road,
Suite 202 , Santa Clarita, CA 91387
(Address
of principal executive offices) (Zip Code)
Issuer’s
telephone Number: (661)
251-0001
WITH COPIES TO:
Gregory
Sichenzia, Esq.
Marcelle
S. Balcombe, Esq.
Sichenzia
Ross Friedman Ference LLP
61
Broadway, 32 nd Flr.
New York,
New York 10006
(212)
930-9700
Indicate
by check mark whether the registrant (1) has filed all reports required by
Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes x No o
Indicate
by check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, or a smaller reporting company. See
definitions of “large accelerated filer,” “accelerated filer” and “smaller
reporting company” in Rule 12b-2 of the Exchange Act.
Large
accelerated filer o
|
Accelerated
filer o
|
Non-accelerated
filer o
|
Smaller
reporting company x
|
Indicate
by check mark whether the registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act). Yes o No x
The
number of shares of registrant’s common stock outstanding, as of July 31, 2008
was 132,666,777.
BIOSLAR, INC.INDEX
|
||
ITEM
1:
|
FINANCIAL
STATEMENTS (Unaudited)
|
|
|
Balance
Sheets
|
3
|
|
Statements
of Operations
|
4
|
|
Statement
of Shareholders' Equity
|
5
|
|
Statements
of Cash Flows
|
6
|
|
Notes
to the Financial Statements
|
7
|
ITEM
2:
|
MANAGEMENT’S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
|
9
|
ITEM
3:
|
QUANTITATIVE
AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
|
12
|
ITEM
4:
|
CONTROLS
AND PROCEDURES
|
12
|
PART II: OTHER
INFORMATION
|
|
|
Item
1:
|
LEGAL
PROCEEDINGS
|
12
|
ITEM
1A:
|
RISK
FACTORS
|
12
|
ITEM
2:
|
UNREGISTERED
SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
|
12
|
ITEM
3:
|
DEFAULTS
UPON SENIOR SECURITIES
|
13
|
ITEM
4:
|
SUBMISSION
OF MATTERS TO A VOTE OF SECURITY HOLDERS
|
13
|
ITEM
5:
|
OTHER
INFORMATION
|
13
|
EXHIBITS
|
13
|
|
|
14
|
PART I –FINANCIAL
INFORMATION
ITEM 1. FINANCIAL
STATEMENTS
BIOSOLAR, INC.
(A Development Stage
Company)
FINANCIAL
STATEMENTS
JUNE 30, 2008
(A Development Stage
Company)
BALANCE SHEETS
JUNE
30, 2008
(Unaudited)
|
||||||||
06/30/08
|
12/31/07
|
|||||||
ASSETS
|
||||||||
CURRENT
ASSETS
|
||||||||
Cash
& cash equivalents
|
$ |
107,480
|
$ |
340,484
|
||||
Certificates
of deposits
|
466,071
|
653,867
|
||||||
Inventory,
work in progress
|
60,078
|
-
|
||||||
Other
receivable
|
11,207
|
-
|
||||||
Prepaid
expenses
|
55,013
|
80,332
|
||||||
Total
Current Assets
|
699,849
|
1,074,683
|
||||||
PROPERTY
& EQUIPMENT
|
||||||||
Machinery
and equipment
|
49,130
|
-
|
||||||
Computer
|
1,978
|
1,978
|
||||||
Less:
accumulated depreciation
|
(2,298 | ) | (1,029 | ) | ||||
Net
Property and Equipment
|
48,810
|
949
|
||||||
OTHER
ASSETS
|
||||||||
Patents
|
18,760
|
7,265
|
||||||
Deposit
|
770
|
770
|
||||||
TOTAL
OTHER ASSETS
|
19,530
|
8,035
|
||||||
TOTAL
ASSETS
|
$ |
768,189
|
$ |
1,083,667
|
||||
LIABILITIES
AND SHAREHOLDERS' EQUITY
|
||||||||
CURRENT
LIABILITIES
|
||||||||
Accounts
Payable
|
$ |
19,195
|
$ |
-
|
||||
Accrued
expenses
|
5,807
|
9,611
|
||||||
Credit
card payable
|
-
|
995
|
||||||
TOTAL
CURRENT LIABILITIES
|
25,002
|
10,606
|
||||||
SHAREHOLDERS'
EQUITY
|
||||||||
Common
stock, $0.0001 par value;
|
||||||||
500,000,000
authorized common shares
|
||||||||
132,226,777
and 131,706,777 shares issued and outstanding
|
13,222
|
13,170
|
||||||
Additional
paid in capital
|
2,311,905
|
2,181,958
|
||||||
Deficit
accumulated during the development stage
|
(1,581,940 | ) | (1,122,067 | ) | ||||
TOTAL
SHAREHOLDERS' EQUITY
|
743,187
|
1,073,061
|
||||||
TOTAL
LIABILITIES AND SHAREHOLDERS' EQUITY
|
$ |
768,189
|
$ |
1,083,667
|
The accompanying notes are an integral part of these
financial statements
3
BIOSOLAR, INC.
(A Development Stage
Company)
STATEMENTS OF
OPERATIONS
(Unaudited)
From
Inception
|
||||||||||||||||||||
April
24, 2006
|
||||||||||||||||||||
Three
Months Ended
|
Six
Months Ended
|
through
|
||||||||||||||||||
06/30/08
|
06/30/07
|
06/30/08
|
06/30/07
|
June
30, 2008
|
||||||||||||||||
REVENUE
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||
OPERATING
EXPENSES
|
||||||||||||||||||||
Selling
and marketing expenses
|
110,333
|
8,660
|
158,511
|
18,944
|
479,133
|
|||||||||||||||
General
and administrative expenses
|
125,600
|
76,063
|
250,945
|
160,829
|
902,575
|
|||||||||||||||
Research
& Development
|
28,523
|
72,713
|
62,151
|
100,004
|
272,184
|
|||||||||||||||
Depreciation
and amortization
|
1,174
|
-
|
1,269
|
633
|
2,339
|
|||||||||||||||
TOTAL
OPERATING EXPENSES
|
265,630
|
157,436
|
472,876
|
280,410
|
1,656,231
|
|||||||||||||||
LOSS
FROM OPERATIONS BEFORE OTHER INCOME
|
(265,630 | ) | (157,436 | ) | (472,876 | ) | (280,410 | ) | (1,656,231 | ) | ||||||||||
TOTAL
OTHER INCOME
|
||||||||||||||||||||
Interest
income
|
5,411
|
10,062
|
13,803
|
22,957
|
75,891
|
|||||||||||||||
LOSS
BEFORE PROVISION FOR TAXES
|
(260,219 | ) | (147,374 | ) | (459,073 | ) | (257,453 | ) | (1,580,340 | ) | ||||||||||
Provision
for income taxes
|
(800 | ) |
-
|
(800 | ) | (800 | ) | (1,600 | ) | |||||||||||
NET
LOSS
|
$ | (261,019 | ) | $ | (147,374 | ) | $ | (459,873 | ) | $ | (258,253 | ) | $ | (1,581,940 | ) | |||||
BASIC
AND DILUTED LOSS PER SHARE
|
$ | (0.00 | ) | $ | (0.00 | ) | $ | (0.00 | ) | $ | (0.00 | ) | ||||||||
WEIGHTED-AVERAGE
COMMON SHARES OUTSTANDING
|
||||||||||||||||||||
BASIC
AND DILUTED
|
131,750,733
|
128,557,777
|
131,728,755
|
128,557,777
|
||||||||||||||||
The accompanying notes are an integral part of these
financial statements
4
BIOSOLAR, INC.
(A Development Stage
Company)
STATEMENT OF SHAREHOLDERS'
EQUITY
(Unaudited)
Deficit
|
||||||||||||||||||||
Accumulated
|
||||||||||||||||||||
Additional
|
during
the
|
|||||||||||||||||||
Common
stock
|
Paid-in
|
Development
|
||||||||||||||||||
Shares
|
Amount
|
Capital
|
Stage
|
Total
|
||||||||||||||||
Balance
at December 31, 2007
|
131,706,777
|
$ |
13,170
|
$ |
2,181,957
|
$ | (1,122,067 | ) | $ |
1,073,060
|
||||||||||
Issuance
of common shares in June 2008 for cash
|
||||||||||||||||||||
(520,000
common shares issued at $0.25 per share ) (unaudited)
|
520,000
|
52
|
129,948
|
-
|
130,000
|
|||||||||||||||
Net
Loss (unaudited)
|
-
|
-
|
-
|
(459,873 | ) | (459,873 | ) | |||||||||||||
Balance
at June 30, 2008 (unaudited)
|
132,226,777
|
$ |
13,222
|
$ |
2,311,905
|
$ | (1,581,940 | ) | $ |
743,187
|
The accompanying notes are an integral part of these
financial statements
5
BIOSOLAR, INC.
(A Development Stage
Company)
STATEMENTS OF CASH
FLOWS
(Unaudited)
Six
Months
Ended
|
Six
Months
Ended
|
From
Inception April 24,
2006 |
||||||||||
June
30, 2008
|
June
30, 2007
|
June
30, 2008
|
||||||||||
CASH
FLOWS FROM OPERATING ACTIVITIES:
|
||||||||||||
Net
loss
|
$ | (459,873 | ) | $ | (258,253 | ) | $ | (1,581,940 | ) | |||
Adjustment
to reconcile net loss to net cash
|
||||||||||||
used
in operating activities
|
||||||||||||
Depreciation
expense
|
1,269
|
633
|
2,298
|
|||||||||
Issuance
of stock for services
|
-
|
-
|
212,260
|
|||||||||
(Increase)
Decrease in:
|
||||||||||||
Inventory
|
(60,078 | ) |
-
|
(60,078 | ) | |||||||
Other
receivable
|
(11,207 | ) |
-
|
(11,207 | ) | |||||||
Prepaid
expenses
|
25,319
|
(13,277 | ) | (55,013 | ) | |||||||
Deposits
|
-
|
-
|
(770 | ) | ||||||||
Patents
|
(11,495 | ) |
-
|
(18,760 | ) | |||||||
Increase
(Decrease) in:
|
||||||||||||
Accounts
Payable
|
19,195
|
(37,179 | ) |
19,195
|
||||||||
Accrued
Expenses
|
(3,805 | ) |
6,904
|
5,807
|
||||||||
Credit Card Payable
|
(995 | ) | (2,917 | ) |
-
|
|||||||
NET
CASH USED IN OPERATING ACTIVITIES
|
(501,670 | ) | (304,089 | ) | (1,488,208 | ) | ||||||
NET
CASH FLOWS USED IN INVESTING ACTIVITIES:
|
||||||||||||
Purchase
of Equipment
|
(49,130 | ) |
-
|
(51,108 | ) | |||||||
Investment
in Certificate of Deposits
|
187,796
|
178,159
|
(466,071 | ) | ||||||||
NET
CASH (USED)/PROVIDED BY INVESTING ACTIVITIES
|
138,666
|
178,159
|
(517,179 | ) | ||||||||
NET
CASH FLOWS FROM FINANCING ACTIVITIES:
|
||||||||||||
Proceeds
from issuance of common stock
|
130,000
|
-
|
2,112,867
|
|||||||||
NET
CASH PROVIDED BY FINANCING ACTIVITIES
|
130,000
|
-
|
2,112,867
|
|||||||||
NET
INCREASE (DECREASE) IN CASH
|
(233,004 | ) | (125,930 | ) |
107,480
|
|||||||
CASH,
BEGINNING OF PERIOD
|
340,484
|
200,739
|
-
|
|||||||||
CASH,
END OF PERIOD
|
$ |
107,480
|
$ |
74,809
|
$ |
107,480
|
||||||
SUPPLEMENTAL
DISCLOSURES OF CASH FLOW INFORMATION
|
||||||||||||
Interest
paid
|
$ |
-
|
$ |
-
|
$ |
-
|
||||||
Taxes
paid
|
$ |
800
|
$ |
800
|
$ |
1,600
|
The accompanying notes are an integral part of these financial statements
6
BIOSOLAR, INC.
(A Development Stage
Company)
NOTES TO FINANCIAL
STATEMENTS-UNAUDITED
JUNE 30, 2008
1. Basis of
Presentation
The accompanying unaudited financial statements have been prepared
in accordance with accounting principles generally accepted in the United States
of America for interim financial information and with the instructions to Form
10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not
include all of the information and footnotes required by generally accepted
accounting principles for complete financial statements. In the opinion of
management, all normal recurring adjustments considered necessary for a fair
presentation have been included. Operating results for the six month
period ended June 30, 2008 are not necessarily indicative of the results that
may be expected for the year ending December 31, 2008. For further
information refer to the financial statements and footnotes thereto included in
the Company's Form 10-K for the year ended December 31, 2007.
Going
Concern
The accompanying financial statements have been prepared on a
going concern basis of accounting, which contemplates continuity of operations,
realization of assets and liabilities and commitments in the normal course of
business. The accompanying financial statements do not reflect any
adjustments that might result if the Company is unable to continue as a going
concern. The Company does not generate significant revenue, and has
negative cash flows from operations, which raise substantial doubt about the
Company’s ability to continue as a going concern. The ability of the
Company to continue as a going concern and appropriateness of using the going
concern basis is dependent upon, among other things, additional cash
infusion. As discussed in Note 3, the Company has obtained funds from
its shareholders since its’ inception through June 30, 2008. It is Management's
plan to generate additional working capital from investors, and then continue to
pursue its business plan and purposes.
2. SUMMARY OF
SIGNIFICANT ACCOUNTING POLICIES
This summary of significant accounting policies of Carbon
Sciences, Inc. is presented to assist in understanding the Company’s financial
statements. The financial statements and notes are representations of the
Company’s management, which is responsible for their integrity and objectivity.
These accounting policies conform to accounting principles generally accepted in
the United States of America and have been consistently applied in the
preparation of the financial statements.
Development Stage Activities
and Operations
The Company is in its initial stages of formation and has
insignificant revenues. FASB #7 defines a development stage activity as one in
which all efforts are devoted substantially to establishing a new business and
even if planned principal operations have commenced, revenues are
insignificant.
Revenue
Recognition
The Company will recognize revenue when services are performed,
and at the time of shipment of products, provided that evidence of an
arrangement exists, title and risk of loss have passed to the customer, fees are
fixed or determinable, and collection of the related receivable is reasonably
assured. To date, the Company has had no revenues and is in the development
stage.
Cash and
Cash Equivalent
The Company considers all highly liquid investments with an
original maturity of three months or less to be cash equivalents.
Investments
Certificate of Deposits with banking institutions are short-term
investments with initial maturities of more than 90 days. The carrying amount of
these investments is a reasonable estimate of fair value due to their short-term
nature.
7
2. SUMMARY OF
SIGNIFICANT ACCOUNTING POLICIES (Continued)
Loss per
Share Calculations
The Company adopted Statement of Financial Standards (“SFAS”) No.
128 for the calculation of “Loss per Share”. SFAS No. 128 dictates
the calculation of basic earnings per share and diluted earnings per share.
Basic earnings per share are computed by dividing income available to common
shareholders by the weighted-average number of common shares available. Diluted
earnings per share is computed similar to basic earnings per share except that
the denominator is increased to include the number of additional common shares
that would have been outstanding if the potential common shares had been issued
and if the additional common shares were dilutive. The Company’s diluted loss
per share is the same as the basic loss per share for the period ended June 30,
2008 as the inclusion of any potential shares would have had an anti-dilutive
effect due to the Company generating a loss.
Reclassification
The expenses for the six months ended June 30, 2007 were
reclassified to conform with the expenses for the six months ended June 30,
2008.
3. CAPITAL STOCK
During the six months ended June 30, 2008, the Company issued
520,000 shares of common stock at a purchase price of $0.25 per share pursuant
to a private placement made pursuant to Rule 506 of Regulation D promulgated
under section 4(2) of the Securities Act of 1933, as amended.
4. INCOME TAXES
The Company files income tax returns in the U.S. Federal
jurisdiction, and the state of California. With few exceptions, the Company is
no longer subject to U.S. federal, state and local, or non-U.S. income tax
examinations by tax authorities for years before 2004.
The Company adopted the provisions of FASB Interpretation No. 48,
Accounting for Uncertainty in Income Taxes, on January 1,
2007. Deferred income taxes have been provided by temporary
differences between the carrying amounts of assets and liabilities for financial
reporting purposes and the amounts used for tax purposes. To the extent allowed
by GAAP, we provide valuation allowances against the deferred tax assets for
amounts when the realization is uncertain.
Included in the balance at June 30, 2008, are no tax positions for
which the ultimate deductibility is highly certain but for which there is
uncertainty about the timing of such deductibility.
The Company's policy is to recognize interest accrued related to
unrecognized tax benefits in interest expense and penalties in operating
expenses.
5.
SUBSEQUENT EVENTS
During July 2008, the Company issued 440,000 shares of common
stock for $0.25 per share in the amount of $110,000, pursuant to a private
placement made pursuant to Rule 506 of Regulation D promulgated under section
4(2) of the Securities Act of 1933, as amended.
8
UPDATE
Certain
statements contained herein constitute forward-looking statements. In some
cases, you can identify forward-looking statements by terminology such as "may,"
"will," "should," "expect," "plan," "anticipate," "believe," "estimate,"
"predict," "potential" or "continue," the negative of such terms, or other
comparable terminology. All statements other than statements of historical fact
made in this report are forward looking. In particular, the statements herein
regarding industry prospects and future results of operations or financial
position are forward-looking statements. Because such statements include risks
and uncertainties, actual results may differ materially from those expressed or
implied by such forward-looking statements as a result of certain factors,
including, but not limited to, risks associated with the integration of
businesses following an acquisition, competitors with broader product lines and
greater resources, emergence into new markets, the termination of any of our
significant contracts, our inability to maintain working capital requirements to
fund future operations, or our inability to attract and retain highly qualified
management, technical and sales personnel.
Overview
We are
developing an innovative technology to produce bio-based materials from
renewable plant sources that will reduce the cost per watt of Photovoltaic solar
cells. Most of the solar industry is focused on photovoltaic efficiency to
reduce cost, but we are introducing a new dimension of cost reduction by
replacing petroleum-based plastic solar cell components with durable bio-based
plastics. The process for producing electricity from sunlight is known as
Photovoltaics. Photovoltaic ("PV") is the science of capturing and
converting sun light into electricity.
We are
focusing our research and product development efforts on producing bio-based
components that meet the thermal and durability requirements of current solar
cell manufacturing processes for conventional crystalline cell designs as well
as thin film PV devices in an effort to capitalize on what we perceive as cost
advantages to current petroleum based solar cell components.
We are
focusing our research and product development efforts on bio-based backsheets,
substrates, superstrates, module, panel components, and the eventual expansion
of such products to the building materials.
We were
incorporated in the State of Nevada on April 24, 2006, as BioSolar Labs, Inc.
Our name was changed to BioSolar, Inc. on June 8, 2006. Our principal executive
offices are located at 27936 Lost Canyon Road, Suite 202, Santa Clarita,
California 91387, and our telephone number is (661) 251-0001. Our fiscal
year end is December 31.
Application of Critical Accounting
Policies
Our
discussion and analysis of our financial condition and results of operations are
based upon our financial statements, which have been prepared in accordance with
accounting principles generally accepted in the United States of America. The
preparation of these financial statements requires us to make estimates and
judgments that affect the reported amounts of assets, liabilities, revenues and
expenses, and related disclosures of contingent assets and liabilities. On an
ongoing basis, we evaluate our estimates, including those related to impairment
of property, plant and equipment, intangible assets, deferred tax assets and
fair value computation using the Black Scholes option pricing model. We base our
estimates on historical experience and on various other assumptions, such as the
trading value of our common stock and estimated future undiscounted cash flows,
that we believe to be reasonable under the circumstances, the results of which
form the basis for making judgments about the carrying value of assets and
liabilities that are not readily apparent from other sources. Actual results may
differ from these estimates under different assumptions or conditions; however,
we believe that our estimates, including those for the above-described items,
are reasonable.
9
Use of Estimates
In
accordance with accounting principles generally accepted in the United States,
management utilizes estimates and assumptions that affect the reported amounts
of assets and liabilities and the disclosure of contingent assets and
liabilities at the date of the financial statements as well as the reported
amounts of revenues and expenses during the reporting period. Actual results
could differ from those estimates. These estimates and assumptions relate to
recording net revenue, collectibility of accounts receivable, useful lives and
impairment of tangible and intangible assets, accruals, income taxes, inventory
realization, stock-based compensation expense and other factors. Management
believes it has exercised reasonable judgment in deriving these estimates.
Consequently, a change in conditions could affect these estimates.
Fair Value of Financial
Instruments
Our cash,
cash equivalents, investments, accounts receivable and accounts payable are
stated at cost which approximates fair value due to the short-term nature of
these instruments.
In
December 2004, the FASB issued Statement of Financial Accounting Standards No.
123R, Share-based Payment. SFAS 123R revises SFAS 123 and supersedes APB 25.
SFAS 123R will be effective for the year ending December 31, 2006, and applies
to transactions in which an entity exchanges its equity instruments for goods or
services and also applies to liabilities an entity may incur for goods or
services that are to follow a fair value of those equity instruments. Under SFAS
123R, we will be required to follow a fair value approach using an
option-pricing model, such as the Black Scholes option valuation model, at the
date of a stock option grant. The deferred compensation calculated under the
fair value method would then be amortized over the respective vesting period of
the stock option. The adoption of SFAS 123R will not have a material impact on
our results of operations.
Recently Issued Accounting
Pronouncements
10
RESULTS OF OPERATIONS – THREE AND SIX
MONTHS ENDED JUNE 30, 2008 COMPARED TO THE THREE AND SIX MONTHS ENDED JUNE 30,
2007
OPERATING
EXPENSES
Selling and Marketing
Expenses
Selling
and marketing (“S&M”) expenses increased by $101,673 or 1174.05%, to
$110,333 for the three months ended June 30, 2008, compared to the prior period.
S&M expenses increased by $139,567 or 737%, to $158,511 for the six months
ended June 30, 2008, compared to the prior period. S&M expenses increased
due to an increase in marketing exposure.
General and Administrative
Expenses
General
and administrative (“G&A”) expenses increased by $49,537 or 65.13%, to
$125,600 for the three months ended June 30, 2008, compared to the prior period.
G&A expenses increased by $90,116 or 56.03%, to $250,945 for the six months
ended June 30, 2008, compared to the prior period. This increase in G&A
expenses was the result of an increase in salaries and professional
fees.
Research and
Development
Research
and Development (“R&D”) expenses decreased by $44,190 or 60.77%, to $28,523
for the three months ended June 30, 2008, compared to the prior period. R&D
expenses decreased by $37,853 or 37.85%, to $62,151 for the six months ended
June 30, 2008, compared to the prior period. This decrease in R&D expenses
was the result of a decrease in fees paid to consultants and testing of
products.
Net
Loss
Our net
loss increased by $113,645 to $261,019 for the three months ended June 30, 2008,
compared to the prior period. Net loss increased by $201,620 to $459,873 for the
six months ended June 30, 2008, compared to the prior period. Currently the
Company is in its development stage and had no revenues.
LIQUIDITY AND CAPITAL
RESOURCES
As of
June 30, 2008, we had $674,847 of working capital as compared to
$1,064,076 as of December 31, 2007. This decrease of $389,229 was due
primarily to use of funds for operating activities.
Net cash
used in operating activities was $501,670 for the six months ended June 30,
2008, as compared to cash used of $304,089 for the prior period. This increase
of $197,581 was primarily attributable to an increase in general and
administrative expenses.
Net cash
provided by investing activities was $138,666 for the six months ended June 30,
2008, as compared to cash provided of $178,159 for the prior period. The
decrease of cash provided in investing activities was primarily due to a
decrease in investing in certificate of deposits and the purchase of
equipment.
Net cash
provided from financing activities during the six months ended June 30, 2008,
and 2007 was $130,000 and $0 respectively. The increase in cash provided from
financing activities was due to equity financing.
PLAN OF OPERATION AND FINANCING
NEEDS
We are
engaged in the development of new and innovative technology to produce bio-based
materials with the intent to reduce the cost per watt of solar cells that
convert sun light into electrical energy. We plan to develop bio-based
backsheets, substrates, superstrate layer, module, panel components, and
thereafter focus our efforts on establishing markets in the building
materials.
11
Our plan
of operation within the next twelve months is to utilize our cash balances to
transition from research and development stage to a production stage for the
bio-based plastic backsheets and substrates to reduce the cost of solar cells
that convert sun light into electrical energy. In addition, during the next
twelve months we plan to accelerate the development activity for other solar
cell components, commence a test program to determine the physical properties
and characteristics that will be most suitable for commercially available solar
cell devices, and build prototype solar cells, as we attempt to validate the
commercial viability of additional bio-based solar cell components. We believe
that our current cash and investment balances will be sufficient to support
development activity and general and administrative expenses for the next twelve
months. Management estimates that it will require additional cash resources
during 2008, based upon its current operating plan and condition. We will be
investigating additional financing alternatives, including equity and/or debt
financing. There is no assurance that capital in any form would be available to
us, and if available, on terms and conditions that are acceptable. If we are
unable to obtain sufficient funds during the next twelve months, we may be
forced to reduce the size of our organization, which could have a material
adverse impact on, or cause us to curtail and/or cease, the development of our
products.
Off-Balance Sheet
Arrangements
We do not
have any off balance sheet arrangements that are reasonably likely to have a
current or future effect on our financial condition, revenues, results of
operations, liquidity or capital expenditures.
ITEM 3. QUANTITATIVE AND QUALITATIVE
DISCLOSURES ABOUT MARKET RISK
n/a
As of the
end of the period covered by this report, we conducted an evaluation, under the
supervision and with the participation of our chief executive officer and chief
financial officer of our disclosure controls and procedures (as defined in Rule
13a-15(e) and Rule 15d-15(e) of the Exchange Act). Based upon this evaluation,
our chief executive officer and chief financial officer concluded that our
disclosure controls and procedures are effective to ensure that information
required to be disclosed by us in the reports that we file or submit under the
Exchange Act is: (1) accumulated and communicated to our management, including
our chief executive officer and chief financial officer, as appropriate to allow
timely decisions regarding required disclosure; and (2) recorded, processed,
summarized and reported, within the time periods specified in the Commission's
rules and forms. There was no change to our internal controls or in other
factors that could affect these controls during our last fiscal quarter that has
materially affected, or is reasonably likely to materially affect, our internal
control over financial reporting.
PART II - OTHER
INFORMATION
ITEM 1. LEGAL
PROCEEDINGS
None.
There are
no material changes from the risk factors previously disclosed in the
Registrant’s Form 10-K filed on March 31, 2008.
None
12
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None
ITEM 4. SUBMISSION OF MATTERS TO A
VOTE OF SECURITY HOLDERS
|
Description
|
|
|
|
|
|
Articles
of Incorporation of Biosolar Labs, Inc. filed with the Nevada
Secretary of State on April 24, 2006. (Incorporated by reference to the
Company’s Registration Statement on Form SB-2 filed with the SEC on
November 22, 2006)
|
|
|
|
|
3.2
|
|
Articles
of Amendment of Articles of Incorporation of Biosolar Labs, Inc. filed
with the Nevada Secretary of State on May 25, 2006. (Incorporated by
reference to the Company’s Registration Statement on Form SB-2 filed with
the SEC on November 22, 2006)
|
|
|
|
3.3
|
|
Articles
of Amendment of Articles of Incorporation of Biosolar Labs, Inc. filed
with the Nevada Secretary of State on June 8, 2006. (Incorporated by
reference to the Company’s Registration Statement on Form SB-2 filed with
the SEC on November 22, 2006)
|
|
|
|
3.4
|
|
Bylaws
of Biosolar, Inc.( Incorporated by reference to the Company’s Registration
Statement on Form SB-2 filed with the SEC on November 22,
2006)
|
|
|
|
|
Form
of Subscription Agreement dated as of May 26, 2006. (Incorporated by
reference to the Company’s Registration Statement on Form SB-2 filed with
the SEC on November 22, 2006)
|
|
|
|
|
10.2
|
|
Form
of Subscription Agreement dated as of July 17, 2006. (Incorporated by
reference to the Company’s Registration Statement on Form SB-2 filed with
the SEC on November 22, 2006)
|
|
|
|
10.3
|
|
Form
of Subscription Agreement dated as of October 11, 2006. (Incorporated by
reference to the Company’s Registration Statement on Form SB-2 filed with
the SEC on November 22, 2006)
|
|
|
|
14.1
|
|
Code
of Ethics (Incorporated by reference to the Company’s Form 10-K filed with
the SEC on March 25, 2008 )
|
|
|
|
31.1
|
|
Certification
by Chief Executive Officer and Acting Chief Financial Officer pursuant to
Sarbanes-Oxley Section 302 (filed herewith).
|
|
|
|
32.1
|
|
Certification
by Chief Executive Officer and Acting Chief Financial Officer pursuant to
18 U.S.C. Section 1350 (filed
herewith).
|
13
SIGNATURES
In
accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused
this report to be signed on its behalf by the undersigned, thereunto duly
authorized, in the City of Los Angeles, State of California, on August 1,
2008.
|
BIOSOLAR
|
|
|
|
|
By:
|
/s/ David
Lee
|
|
|
Chief
Executive Officer (Principal Executive Officer
) and
Acting
Chief Financial Officer
(Principal
Financial Officer and Principal Accounting
Officer)
|
14